XENE Stock: Insider Activity, Filings & Research

Xenon Pharmaceuticals Inc. (XENE) — Drillr’s hub for XENE insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, XENE insiders filed 0 open-market buys and 15 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$17.8M

Insider trades by month Buys Sells

Jan

Jun

Oct

Dec

Jan

Mar

Context3-month price +24.2%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
Jun 3, 2026	GANNON STEVENdirector	Grant	1,593	—
Jun 3, 2026	GAROFALO ELIZABETH A.director	Grant	10,507	$53.46
Jun 3, 2026	Svoronos Dawndirector	Tax	1,416	$53.41
Jun 3, 2026	Cannon Gilliandirector	Grant	1,593	—
Jun 3, 2026	Machado Patrickdirector	Grant	1,593	—
Jun 3, 2026	Svoronos Dawndirector	Grant	10,507	$53.46
Jun 3, 2026	PATOU GARYdirector	Option	2,645	—
Jun 3, 2026	GANNON STEVENdirector	Grant	10,507	$53.46
Jun 3, 2026	GANNON STEVENdirector	Tax	1,416	$53.41
Jun 3, 2026	GAROFALO ELIZABETH A.director	Option	2,645	—
Jun 3, 2026	Svoronos Dawndirector	Grant	1,593	—
Jun 3, 2026	GAROFALO ELIZABETH A.director	Grant	1,593	—
Jun 3, 2026	PATOU GARYdirector	Grant	1,593	—
Jun 3, 2026	Gover Justin D.director	Grant	10,507	$53.46
Jun 3, 2026	Cannon Gilliandirector	Option	2,645	—

Source: XENE SEC Form 4 filings, latest Jun 3, 2026. For informational purposes only — not investment advice.

Overview

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Burnaby, Canada. The company specializes in developing neurological therapeutics by targeting ion channels, particularly potassium and sodium channels in the brain. Xenon has built its expertise around understanding the genetic basis of neurological disorders and translating these insights into targeted drug therapies. The company went public in 2014 and has since advanced multiple drug candidates through clinical trials, with its lead program azetukalner (XEN1101) currently in Phase 3 trials for epilepsy and depression.

Business

Xenon Pharmaceuticals operates in the neurological drug development sector, focusing on ion channel modulators - drugs that affect the electrical activity of nerve cells in the brain. Ion channels are protein structures that control the flow of electrically charged particles (ions) across cell membranes, and their dysfunction is implicated in many neurological and psychiatric disorders. The company's approach centers on developing drugs that target specific types of ion channels: Kv7 potassium channels and various sodium channels (Nav1.1, Nav1.6, Nav1.7). When these channels malfunction due to genetic mutations or other factors, they can cause seizures, depression, pain, and other neurological symptoms. Xenon's drugs work by either opening or blocking these channels to restore normal brain function. Xenon's clinical pipeline includes several key programs: 1. Azetukalner (XEN1101) - A Kv7 potassium channel opener that represents approximately 80-90% of the company's focus. This drug is in Phase 3 trials for focal epilepsy and Phase 3 trials for major depressive disorder, with plans for bipolar depression studies. 2. XEN496 - Another Kv7 channel opener in Phase 3 trials specifically for KCNQ2 developmental and epileptic encephalopathy, a rare genetic form of childhood epilepsy. 3. Early-stage sodium channel programs - Including XEN1120 (Kv7 for pain), XEN1701 (Nav1.7 for pain), and Nav1.1 programs for Dravet syndrome, representing roughly 10-20% of development efforts. The company also has a collaboration with Neurocrine Biosciences for sodium channel inhibitor development, which provides additional validation and potential revenue through milestone payments.

Revenue model

Xenon Pharmaceuticals operates on a traditional biopharmaceutical business model, generating revenue primarily through milestone payments from collaboration agreements and eventual product sales once drugs receive regulatory approval. Currently, the company has minimal revenue, receiving occasional milestone payments from its partnership with Neurocrine Biosciences ($7.5 million in Q1 2025). The company's primary revenue opportunity lies in commercializing azetukalner for epilepsy, where the addressable market includes approximately 3 million people with epilepsy in the United States alone. The epilepsy drug market is substantial, with existing competitors like Xcopri generating over $320 million annually. For depression, the market is even larger, representing a multi-billion dollar opportunity given that major depressive disorder affects roughly 8% of adults. Xenon's business model faces several key margin influencers. Positive factors include the company's focus on genetically-validated targets, which historically have higher success rates in clinical trials, and the potential for premium pricing given the significant unmet medical need in treatment-resistant epilepsy and depression. The company's once-daily dosing without titration requirements could provide competitive advantages. Negative factors include the high cost and risk of Phase 3 clinical trials, intense competition from established pharmaceutical companies, and the challenge of demonstrating differentiation in crowded therapeutic areas. The company's current cash burn rate of approximately $60-70 million per quarter reflects the substantial investment required to advance multiple clinical programs simultaneously. Future profitability will depend on successful Phase 3 trial outcomes, regulatory approvals, and the company's ability to either commercialize independently or secure favorable licensing deals with larger pharmaceutical partners.

Competitive moat

Xenon Pharmaceuticals possesses a moderate but narrowing moat based primarily on its scientific expertise and intellectual property position in ion channel modulation. The company's core competitive advantage stems from its deep understanding of the genetic basis of neurological disorders and its ability to translate genetic insights into targeted therapies. This expertise, built over nearly three decades, provides meaningful barriers to entry for companies without similar genetic and electrophysiology capabilities. The company's intellectual property portfolio around Kv7 channel modulators and specific sodium channel targets creates some protection, though patents in the pharmaceutical industry have finite lives and can be challenged. Xenon's early mover advantage in certain genetic epilepsy syndromes and its clinical data package representing over 700 patient years of exposure provide regulatory and commercial advantages that competitors would need years to replicate. However, the moat faces significant threats. Large pharmaceutical companies with substantially greater resources are increasingly focused on neurological disorders, and several competitors are developing drugs targeting similar mechanisms. The ion channel field is becoming more crowded, with companies like Neurocrine, Takeda, and others advancing competing programs. Additionally, once azetukalner's mechanism of action is fully validated through successful Phase 3 trials, it may attract more competition from companies developing follow-on compounds. The company's partnership with Neurocrine, while providing validation and funding, also creates a situation where Xenon is essentially training a much larger competitor in its core area of expertise. The durability of Xenon's moat will largely depend on its ability to successfully commercialize azetukalner and continue innovating in adjacent ion channel targets before competitors can replicate its advantages.

Risks & safety

Xenon Pharmaceuticals presents a strong financial safety profile with substantial cash reserves but faces the inherent risks of clinical-stage biotechnology development. • Cash position: $691.1 million in cash and marketable securities as of Q1 2025, providing runway into 2027 • Debt levels: Minimal debt with debt-to-equity ratio of 0.012, indicating very low leverage • Current ratio: Exceptionally strong at 64.4x, demonstrating excellent short-term liquidity • Cash burn: Approximately $60-70 million per quarter, manageable given current cash position • Solvency risk: Very low in the near term given substantial cash reserves • Valuation metrics: Trading at 3.8x book value and negative EV/EBITDA due to development stage losses • Graham net-net: Strong at 6.6, indicating the stock trades below liquidation value of current assets • Market position: $2.4 billion market cap provides reasonable scale for biotech sector • Other considerations: Primary risk stems from clinical trial outcomes rather than financial distress; company has sufficient resources to complete key Phase 3 trials; multiple shots on goal with different indications and drug candidates provide some diversification of clinical risk.

Recent development

Over the past few years, Xenon has executed a focused strategy of advancing its lead compound azetukalner through pivotal clinical trials while expanding its pipeline of ion channel modulators. The company has made significant progress transitioning from a research-stage to a late-stage clinical company. The most significant development has been the advancement of azetukalner into multiple Phase 3 programs. In epilepsy, the company initiated the X-TOLE2 and X-TOLE3 studies, with patient recruitment for X-TOLE2 nearing completion and top-line results expected in early 2026. The company has also expanded into neuropsychiatric indications, launching Phase 3 studies in major depressive disorder (X-NOVA2) and preparing to initiate bipolar depression trials. Xenon has strategically broadened its pipeline beyond azetukalner by advancing multiple early-stage ion channel programs. The company has developed next-generation Kv7 modulators with different chemical structures (XEN1120) and advanced sodium channel programs targeting Nav1.7 for pain and Nav1.1 for Dravet syndrome. This diversification reduces dependence on a single asset while leveraging the company's core ion channel expertise. The company has also strengthened its financial position through successful capital raises, building a cash position of nearly $700 million that provides runway into 2027. This financial strength allows Xenon to maintain control over its key programs while having flexibility to pursue partnership opportunities from a position of strength. Recent organizational changes include the planned departure of CFO Sherry Aulin, reflecting the company's evolution as it prepares for potential commercial activities following successful Phase 3 trials.

XENE company profile · for informational purposes only — not investment advice.

Track XENE with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free